Low Feed Rate Feeder Designed for Pharmaceutical Processes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Low Feed Rate Feeder Designed for Pharmaceutical Processes


Pharmaceutical Technology
Volume 37, Issue 12, pp. 14
The PureFeed DP-4 is a gravimetric feeder that can meter dry pharmaceutical powders at feed rates as low as 20 grams/hour. Jet milling, continuous blending, packaging, coating, and ingredient weighing are applications suited for the DP-4.  A feature of the PureFeed DP-4 is a speed controlled, inert ceramic feed disc. Positioned at the base of a cylindrical, electropolished stainless steel material storage chamber, the disc rotates to discharge tiny amounts of material, continuously and pulsation free over a 20- to 2000-gram feed rate range. All connecting pieces are secured using sanitary quick release clamps and the inlet and discharge of the DP-4 feeder can be sealed to ensure containment during transportation.

Schenck AccuRate

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here